Literature DB >> 18578273

Effective multiple sclerosis management through improved patient assessment.

Amy Perrin Ross1, Natalie Hackbarth, Christine Rohl, Kristi Whitmyre.   

Abstract

Multiple sclerosis (MS) is a complex disease with a wide range of clinical manifestations. Current disease-modifying drugs (DMDs) are effective, but they are associated with effects that may negatively influence treatment compliance. A recent nursing advisory board of MS nurse experts from the Midwest discussed management approaches that can enhance DMD compliance and improve patient satisfaction and quality of life. One such approach is the use of patient questionnaires as tools to assess signs and symptoms of MS and treatment-related adverse effects. Information gained in this manner is beneficial to MS healthcare professionals as well as patients and has the potential to improve treatment compliance and outcomes and disease management.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18578273     DOI: 10.1097/01376517-200806000-00005

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  4 in total

1.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Authors:  O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

2.  Monitoring my multiple sclerosis: a patient-administered health-assessment scale.

Authors:  Elsie E Gulick; Marie Namey; June Halper
Journal:  Int J MS Care       Date:  2011

3.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

Review 4.  Evolving Landscape of Multiple Sclerosis in India: Challenges in the Management.

Authors:  Sudhir Kumar; Anshu Rohatgi; Harshal Chaudhari; Priti Thakor
Journal:  Ann Indian Acad Neurol       Date:  2018 Apr-Jun       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.